arrow
A

Alfonso De Stefano

istituto nazionale tumori - irccs - fondazione g. pascale
H指数:33
被引数:3,627

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis☆

针对左侧、非MSI-H、RAS/BRAF野生型转移性结直肠癌患者,基于抗EGFR的维持治疗与停药再给药的比较:个体患者数据合并分析☆

2026-06-100
OAAI
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI

HER-2基因改变作为接受FOLFIRI治疗的转移性结直肠癌患者的生物标志物

2026-01-010
OA
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

微卫星稳定型结直肠癌中高肿瘤突变负荷的基因组分析揭示了抗-EGFR治疗后MAPK信号通路的改变

2025-10-280
OAAI
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY

短期放疗用于局部晚期直肠癌且不适合化疗的老年患者:SOFT研究

2025-10-250
PRE
Comparison of Single- and Multiport Robot-assisted Approaches in Prostate and Renal Surgery: A Systematic Review and Meta-analysis

单端口与多端口机器人辅助技术在前列腺和肾手术中的应用比较:一项系统评价和Meta分析

2025-09-270
PRE
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study

整合组织与液体活检综合基因组分析以预测抗EGFR疗法在转移性结直肠癌中的疗效:CAPRI-2 GOIM研究的结果

2025-07-120
PRE
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial

液体活检综合基因组分析描绘了转移性结直肠癌的突变景观,以预测CAPRI-2 GOIM试验中FOLFIRI联合西妥昔单抗的抗肿瘤疗效。

2025-04-010
PRE
Genomic alterations on first-line panitumumab plus FOLFIRI in metastatic colorectal cancer
2024-03-220
PRE
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial

Panitumumab联合trifluidine/tipiracil作为难治性RAS野生型转移性结直肠癌患者的抗EGFR再激发疗法: 随机II期VELO试验的总生存率和亚组分析

2023-06-3014
OA
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial
2023-06-011
OA
Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
2023-06-011
OA
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

Regorafenib单药治疗RAS突变型晚期结直肠癌 (STREAM) 患者的二线治疗: 一项学术,多中心,单臂,两阶段,II期研究

2023-02-012
OAAI
Plasma metabolomics, lipidomics and cytokinomics profiling predict disease recurrence in metastatic colorectal cancer patients undergoing liver resection

血浆代谢组学,脂质组学和细胞因子组学分析可预测接受肝切除术的转移性结直肠癌患者的疾病复发

2023-01-119
OAAI
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
2022-10-0111
OAAI